ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

The real-world safety of ruxolitinib in graft-versus-host disease treatment: a pharmacovigilance study based on the FDA adverse event reporting system.

Yuan-Yuan Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.